218 related articles for article (PubMed ID: 16506600)
21. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
22. Education and Imaging. Hepatobiliary and pancreatic: systemic mastocytosis with portal hypertension.
Wong D; Boyapati R; Lokan J; Angus P
J Gastroenterol Hepatol; 2014 Aug; 29(8):1572. PubMed ID: 25073633
[No Abstract] [Full Text] [Related]
23. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
24. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
25. The genetic basis of mast cell activation disease - looking through a glass darkly.
Molderings GJ
Crit Rev Oncol Hematol; 2015 Feb; 93(2):75-89. PubMed ID: 25305106
[TBL] [Abstract][Full Text] [Related]
26. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
27. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.
Pardanani A; Reeder T; Li CY; Tefferi A
Leuk Res; 2003 Oct; 27(10):883-5. PubMed ID: 12860006
[TBL] [Abstract][Full Text] [Related]
28. Systemic mastocytosis.
George TI; Horny HP
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1067-83, vii. PubMed ID: 22054735
[TBL] [Abstract][Full Text] [Related]
29. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
Horny HP; Sotlar K; Valent P
Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
[TBL] [Abstract][Full Text] [Related]
30. Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Marbello L; Anghilieri M; Nosari A; Minola E; Cairoli R; Ricci F; Morra E
Haematologica; 2004 Sep; 89(9):ECR35. PubMed ID: 15377487
[TBL] [Abstract][Full Text] [Related]
31. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Gotlib J; Gerds AT; Bose P; Castells MC; Deininger MW; Gojo I; Gundabolu K; Hobbs G; Jamieson C; McMahon B; Mohan SR; Oehler V; Oh S; Padron E; Pancari P; Papadantonakis N; Pardanani A; Podoltsev N; Rampal R; Ranheim E; Rein L; Snyder DS; Stein BL; Talpaz M; Thota S; Wadleigh M; Walsh K; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2018 Dec; 16(12):1500-1537. PubMed ID: 30545997
[TBL] [Abstract][Full Text] [Related]
32. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).
Pardanani A
Blood; 2013 Apr; 121(16):3085-94. PubMed ID: 23426950
[TBL] [Abstract][Full Text] [Related]
33. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
34. Isolated flushes without permanent, fixed or other skin lesions in patients with systemic mastocytosis: a case series of 9 patients.
Lafont E; Lhermitte L; Damaj G; Soucie E; Barete S; Chandesris MO; Cabaret L; Guichard I; Durieu I; Retornaz F; Sarrot-Reynauld F; Hamidou M; Bruneau J; Aouba A; Dubreuil P; Lortholary O; Asnafi V; Hermine O; Georgin-Lavialle S
Eur J Dermatol; 2015 Apr; 25(2):182-4. PubMed ID: 25547160
[No Abstract] [Full Text] [Related]
35. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
Escribano L; Alvarez-Twose I; Sánchez-Muñoz L; Garcia-Montero A; Núñez R; Almeida J; Jara-Acevedo M; Teodósio C; García-Cosío M; Bellas C; Orfao A
J Allergy Clin Immunol; 2009 Sep; 124(3):514-21. PubMed ID: 19541349
[TBL] [Abstract][Full Text] [Related]
36. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
37. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
[TBL] [Abstract][Full Text] [Related]
38. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.
Pardanani A; Tefferi A
Curr Opin Hematol; 2010 Mar; 17(2):125-32. PubMed ID: 20075725
[TBL] [Abstract][Full Text] [Related]
39. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
40. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.
Florian S; Krauth MT; Simonitsch-Klupp I; Sperr WR; Fritsche-Polanz R; Sonneck K; Födinger M; Agis H; Böhm A; Wimazal F; Horny HP; Valent P
Int Arch Allergy Immunol; 2005 Mar; 136(3):273-80. PubMed ID: 15722637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
